Related Experiment Video
Updated: Jul 19, 2026
Temporal Tracking of Cell Cycle Progression Using Flow Cytometry without the Need for Synchronization
Published on: August 16, 2015
Development of a screening assay for surrogate markers of CHK1 inhibitor-induced cell cycle release
Christie P Fanton1, Michael W Rowe, Edward J Moler
1Biopharma Research and Development, Chiron Corporation, Emeryville, CA, USA. christie.fanton@chiron.com
Abstract:
Chk1 is a key regulator of the S and G2/M checkpoints and is activated following DNA damage by agents such as the topoisomerase I inhibitor camptothecin (CPT). It has been proposed that Chk1 inhibitors used in combination with such a DNA damaging agent to treat tumors would potentiate cytotoxicity and increase the therapeutic index, particularly in tumors lacking functional p53. The aim of this study was to determine whether gene expression analysis could be used to inform lead optimization of a novel series of Chk1 inhibitors. The candidate small-molecule Chk1 inhibitors were used in combination with CPT to identify potential markers of functional Chk1 inhibition, as well as resulting cell cycle progression, using cDNA-based microarrays. Differential expression of several of these putative marker genes was further validated by RT-PCR for use as a medium-throughput assay. In the presence of DNA damage, Chk1 inhibitors altered CPT-dependent effects on the expression of cell cycle and DNA repair genes in a manner consistent with a Chk1-specific mechanism of action. Furthermore, differential expression of selected marker genes, cyclin E2, EGR1, and DDIT3, was dose dependent for Chk1 inhibition. RT-PCR results for these genes following treatment with a panel of Chk1 inhibitors showed a strong correlation between marker gene response and the ability of each compound to abrogate cell cycle arrest in situ following CPT-induced DNA damage. These results demonstrate the utility of global expression analysis to identify surrogate markers, providing an alternative method for rapid compound characterization to support advancement decisions in early drug discovery.
Insights
This study used gene expression analysis to identify markers for Chk1 inhibitors, showing their potential to enhance cancer therapy by targeting cell cycle progression after DNA damage.
Area of Science:
- Molecular Biology
- Cancer Therapeutics
- Drug Discovery
Background:
- Checkpoint kinase 1 (Chk1) regulates cell cycle checkpoints and is activated by DNA damage.
- Chk1 inhibitors combined with DNA damaging agents may improve cancer treatment, especially in p53-deficient tumors.
Purpose of the Study:
- To evaluate gene expression analysis for optimizing novel Chk1 inhibitors.
- To identify markers of Chk1 inhibition and cell cycle effects.
Main Methods:
- Utilized cDNA-based microarrays to analyze gene expression in cells treated with Chk1 inhibitors and camptothecin (CPT).
- Validated differential gene expression using RT-PCR for medium-throughput assays.
- Assessed dose-dependent effects of Chk1 inhibitors on marker gene expression.
Main Results:
- Chk1 inhibitors modulated CPT-induced gene expression related to cell cycle and DNA repair, consistent with Chk1 inhibition.
- Expression of cyclin E2, EGR1, and DDIT3 showed dose-dependent changes with Chk1 inhibition.
- RT-PCR confirmed a strong correlation between marker gene response and the ability of Chk1 inhibitors to overcome CPT-induced cell cycle arrest.
Conclusions:
- Global gene expression analysis is useful for identifying surrogate markers for Chk1 inhibition.
- This approach facilitates rapid compound characterization in early drug discovery for cancer therapeutics.
